|
B-Cell Lymphomas
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Combination treatment reduced the expression of B-cell lymphoma 2 (BCL2), BH3 interacting domain death agonist (BID), and BCL-x/L.
|
30343279 |
2018 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
While caspase-recruitment domain (CARD) membrane-associated guanylate kinase (MAGUK) protein 1 (CARMA1) nucleates B cell lymphoma 10 (BCL10) filament formation through interactions between CARDs, mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a paracaspase with structural similarity to caspases, which recruits TNF receptor-associated factor 6 (TRAF6) for K63-linked polyubiquitination.
|
29382759 |
2018 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
Western blotting was used to examine the levels of apoptotic-associated protein and results indicated that fisetin increased expression of pro-apoptotic proteins such as B-cell lymphoma 2 (BCL2) antagonist/killer (BAK) and BCL2-associated X (BAX) but reduced that of anti-apoptotic protein such as BCL2 and BCL-x, and increased the cleaved forms of caspase-3, -8 and -9, and cytochrome c, apoptosis-inducing factor (AIF) and endonuclease G (ENDO G) in HSC3 cells.
|
29102932 |
2018 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The SNPs in solute carrier family 28 member 3 (SLC28A3), breast cancer 1 (BRCA1), ribonucleotide reductase regulators subunit M2 (RRM2), PMS1 homolog 2 (PMS2), cytidine deaminase (CDA), epoxide hydrolase 1 (EPHX1), heterogenous ribonucleoprotein particle-associated with lethal yellow (RALY), Siglec-3 (CD33), B cell lymphoma 10 (BCL10), ETS variant 1 (ETV1), macrophage stimulating 1 receptor 1 (MST1R), lysine methyltransferase 2B (KMT2B), B cell lymphoma 2 (BCL2), U6 small nuclear RNA-associated Sm-like protein 3 (LSM3), thyroid transcription factor 1 (TTF1) and mitogen-activated protein 3 kinase 1 (MAP3K1) were significantly associated with lymphatic metastasis (P<0.05).
|
28672935 |
2017 |
|
B-Cell Lymphomas
|
0.200 |
AlteredExpression
|
group |
BEFREE |
HFD activated p38 MAPK and increased expression of B-cell lymphoma/CLL 10 (BCL10) and caspase recruitment domain family member 9 (CARD9).
|
28158919 |
2017 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
B-cell lymphoma 10 (BCL10) is not essential for actin polymerisation after FcγR stimulation in human fibroblasts.
|
26774590 |
2016 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Three members of the caspase recruitment domain (CARD) family of adaptors (CARD9, CARD10, and CARD11) are known to form heterotrimers with B-cell lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (MALT1).
|
26277595 |
2015 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-X(L).
|
25139387 |
2014 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Recently, BCL10, originally identified as a recurrent t(1;14)(p22;q32) translocation in MALT B-cell lymphoma, was found to be immunohistochemically positive in some solid tumors, including ACC.
|
23530562 |
2013 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To assess the significance of chromosome translocation t(11;18)(q21;q21), B-cell lymphoma 10 (BCL-10) protein and Helicobacter pylori (H. pylori) infection in gastric mucosa-associated lymphoid tissue (MALT) lymphoma in Colombia.
|
22363141 |
2012 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
Similarly, B-cell lymphoma-X(L) (BCL-X(L)) inhibits caspase activity, but fails to rescue from apoptosis.
|
16957768 |
2007 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Apoptosis regulator B-cell lymphoma 10 (BCL10) may show aberrant nuclear localization in some aggressive extracutaneous MALT lymphomas, often in association with a MALT1 gene t(11;18)(q21;q21) translocation.
|
16784987 |
2006 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
LHGDN |
BCL10 gene amplification associated with strong nuclear BCL10 expression in a diffuse large B cell lymphoma with IGH-BCL2 fusion.
|
16785131 |
2006 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
As discussed in this Review, insight gained from these studies indicates that cFLIP and caspase-8 form a heterodimer that ultimately links T-cell-receptor signalling to activation of nuclear factor-kappaB through a complex that includes B-cell lymphoma 10 (BCL-10), mucosa-associated-lymphoid-tissue lymphoma-translocation gene 1 (MALT1) and receptor-interacting protein 1 (RIP1).
|
16498450 |
2006 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
MALT1, BCL10 (B-cell lymphoma 10), and API2 (apoptosis inhibitor 2)-MALT1 are key molecules in mucosa-associated lymphoid tissue (MALT) lymphomagenesis.
|
16123224 |
2005 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A conditionally active form of B-cell lymphoma 10 (Bcl10) protected WEHI-231 cells from BCR-induced apoptosis upon activation.
|
15878976 |
2005 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
We expressed MALT1 and apoptosis inhibitor-2 API2/MALT1 in human B-cell lymphoma BJAB cells and found both transgenes in membrane lipid rafts along with endogenous MALT1 and 2 binding partners involved in NF-kappa B signaling, B-cell lymphoma 10 (BCL10) and CARMA1 (caspase recruitment domain [CARD]-containing membrane-associated guanylate kinase [MAGUK] 1).
|
15598810 |
2005 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our results, together with recent reports, indicate that BCL10 gene mutations take place in a small population of B-NHL and are not associated with specific histological subtypes.
|
11372735 |
2001 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
BCL10 was found to have truncated mutations at a high frequency in MALT (mucosa-associated lymphoid tissue) B cell lymphomas.
|
10790217 |
2000 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our results suggest that BCL10 mutation may play a pathogenic role in B-cell lymphoma development, particularly in aggressive and antibiotic unresponsive MALT lymphomas, and may further implicate the biologic importance of the carboxyl terminal of the molecule.(Blood.2000;95:3885-3890)
|
10845924 |
2000 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
BEFREE |
Bcl10 is implicated in the regulation of apoptosis and has been reported to be mutated in other subtypes of non-Hodgkin's B-cell lymphoma (B-NHL) and leukaemic cell lines, raising the possibility that its deregulation could be implicated in other forms of haematological malignancy.
|
10886211 |
2000 |
|
B-Cell Lymphomas
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.
|
9989495 |
1999 |
|
B-Cell Lymphomas
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|